Results 211 to 220 of about 26,340 (266)

Comparative Mortality in Heart Failure on Guideline-Directed Medical Therapy Versus Malignant Cancer: A Report From a Global Federated Research Network. [PDF]

J Am Heart Assoc
Monzo L, Baudry G, Duarte K, Hernandez G, Denquin O, Savarese G, Girerd N.   +6 more
europepmc   +1 more source

Comparative efficacy and safety of different SGLT2 inhibitor-based combination strategies in HFrEF: a systematic review and network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Jiang N, Zhang Y, Tang Y, Tan H.
europepmc   +1 more source

Nurse Specialising Consultation in Heart Failure: Impact on Drug Titration and Cardiovascular Events in Patients with Heart Failure and Reduced Ejection Fraction. [PDF]

J Clin Med
Lopez-Aguilera J, Perea-Armijo J, Muñoz-Villarreal AB, Cepas-Sosa A, Luque-Serrano LM, Aguayo-Caño N, Heredia-Campos GM, Martin-Diaz JD, Gonzalez-Manzanares R, Castillo-Dominguez JC, Crespin-Crespin M, Delgado-Ortega M, Ruiz-Ortiz M, Mesa-Rubio D, Pan-Alvarez Osorio M, Anguita-Sanchez M.   +15 more
europepmc   +1 more source

Impact of Sitagliptin on Neprilysin and Glycemic Control in Newly Diagnosed Type 2 Diabetes Patients. [PDF]

Med Sci Monit
Gül CB, Oruc A, Cander S, Aydemir E, Oz Gül O.   +4 more
europepmc   +1 more source

The tale of donanemab: God is in the details. [PDF]

J Alzheimers Dis
Saido TC, Iwata N.
europepmc   +1 more source

Long-term mortality and treatment outcomes in pacemaker-associated heart failure: insights from a nationwide propensity-matched study. [PDF]

Eur Heart J Open
Park YJ, Lee S, Hong S, Kim K, Kim J, Kim JY, Park KM, On YK, Park SJ.   +8 more
europepmc   +1 more source

Angiotensin Receptor Neprilysin Inhibition

JACC: Asia
openaire   +1 more source

A-DEGRADING ENZYME,NEPRILYSIN

A-DEGRADING ENZYME,NEPRILYSIN
openaire